Table 1 Baseline patients characteristics.

From: Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer

First line mCRPC

Docetaxel

p value

Abiraterone or enzalutamide

p value

Grade group 2–4

Grade group 5

Grade group 2–4

Grade group 5

No. patients

74

37

 

91

40

 

Age, median (IQR), years

72 (67–78)

68 (62–74)

0.06

76 (70–81)

74 (66–79)

0.09

ECOG PS, n (%)

0

47 (74.6)

28 (84.9)

 

76 (84.5)

27 (75.0)

 

1

14 (22.2)

4 (12.1)

 

10 (11.1)

6 (16.7)

 

2

2 (3.2)

1 (3.0)

0.33

4 (4.4)

3 (8.3)

0.21

Primary treatment

Radiation

15 (30.0)

4 (23.5)

 

20 (35.1)

3 (14.3)

 

RP

35 (70.0)

13 (76.5)

0.61

37 (64.9)

18 (85.7)

0.07

Extent of disease, n (%)

Bone only

38 (51.3)

10 (27.0)

 

30 (34.1)

9 (22.5)

 

Lymphnode only

11 (14.9)

6 (16.2)

 

30 (34.1)

5 (12.5)

 

Lymphnode + bone

15 (20.3)

16 (43.3)

 

24 (27.3)

23 (57.5)

 

Visceral

10 (13.5)

5 (13.5)

0.03

4 (4.5)

3 (7.5)

0.00

Baseline PSA, median (IQR), ng/ml

32.20 (13.15–95.29)

17.85 (8.67–44.80)

0.25

7.72 (3.22–29.94)

23.00 (5.97–49.28)

0.01

Baseline LDH, median (IQR), IU/l

171 (158–208)

195 (155–230)

0.26

183 (167–204)

189 (168–226)

0.47

Baseline chromogranin, median (IQR), µg/l

165 (65–280)

98 (58–175)

0.82

66 (37–212)

75 (31–144)

0.75

Baseline ALP median (IQR), IU/l

95 (78–150)

104 (68–161)

0.53

95 (68–110)

97 (60–137)

0.78

Time from initial diagnosis to first dose (IQR), months

62.0 (26.5–111.8)

28.1 (19.5–53.7)

0.003

78.4 (37.0–151.4)

31.2 (16.7–79.3)

0.003

  1. IQR Interquartile range, ECOG PS Eastern Cooperative Oncology Group Performance Status, PSA prostate specific antigen, LDH lactate dehydrogenase, ALP alkaline phosphatase, n number.
Back to article page